v3.26.1
Restructuring and Related Costs (Tables)
12 Months Ended
Dec. 31, 2025
Restructuring and Related Activities [Abstract]  
Total Summary of Restructuring, and Related Costs

Total restructuring and related costs from the Restructuring Plans include the following:

 

 

Year Ended

 

 

 

 

December 31, 2025

 

 

 

 

(in thousands)

 

 

 Clinical trial expense and other third-party costs for the deprioritization of
    the luvelta program

 

$

26,149

 

 

 Severance and benefits expense

 

 

15,757

 

 

 Contract termination and other restructuring costs

 

 

9,815

 

 

 Impairment / write-down of long-lived assets and other related costs

 

 

1,694

 

 

 Total

 

$

53,415

 

 

Summary of Severance and Other Termination Benefit Expense and Reconciliation of Such Liability The following table provides details regarding the severance and other termination benefit expense and a reconciliation of such liability for the year ended December 31, 2025, which is reported within accrued compensation on the Balance Sheet:

 

 

 

December 31, 2025

 

 

 

(in thousands)

 

Liability balance as of December 31, 2024

 

$

 

Expense recognized during the period

 

 

12,798

 

Payments during the period

 

 

(9,951

)

Liability balance as of December 31, 2025

 

$

2,847